5 Best Stories on Real Money: Election Chaos, Covid and Copper

Must-reads from Jim Cramer, Helene Meisler, Stephen 'Sarge' Guilfoyle and the Real Money/Real Money Pro team make sense of the market's big moves.
Author:
Publish date:

The election is just days away. The major indexes dropped dramatically this week. And, suddenly, everybody seemed to once again notice the surge in Covid-19.

How should investors and traders position themselves right now -- amid all the uncertainty?

One thing is sure: Don't panic. And don't fall for hyperbole or false prophets. 

Instead, look to voices of reason and expertise amid the turbulent times. Here Real Money and Real Money Pro experts Jim CramerHelene MeislerPaul PriceMaleeha Bengali, and Stephen "Sarge" Guilfoyle provide guidance based on experience and skill, data and indicators. 

Cramer: The Five Bull Markets

We've been down this week, and it's a rocky going, especially as we approach the election and Covid-19 cases surge. But don't panic, says Cramer, we have a group of five bull markets for times like this.

Here they are.

Meisler: It Doesn't Matter Who Wins...

We're likely to see a pullback no matter who takes the White House, says technical analyst Meisler. And, despite what some people believe, the setup today is not like it was in 2016.

Here she shows how the setups differ (even if we decline into Nov. 3).

Price: If It Sounds Too Good to Be True...

...Then it probably is, says Price. First, he picks apart an ad for a retirement investing service that looks just looks too risk-free and too attractive to add up. Then he shows where to put your money for better results. 

Here's Price's strategy for when investors start feeling nervous and desperate

Bengali: Dr. Copper Is Seeing China Right Now

While traditionally a gauge of global health, copper is now weighted toward the Chinese economy, says Bengali. So, as all eyes are on China and its "infrastructure"-led projects, what should investors do?

Here's her take on the metal's new role in the world economy.

Guilfoyle: I'm Long Moderna and Here's Why

The focus when it comes to MRNA is the timing of mRNA-1273, the firm's two-dose hopeful protection against Covid-19, says Guilfoyle. But there's a lot going on with the biotech -- and a lot of promise in global demand for the potential shot.

Here's Guilfoyle's take on Moderna's future.

Real Money and Real Money Pro are TheStreet’s premium sites for active traders. Click here to get great columns like these from Jim Cramer, Jim ‘Rev Shark’ DePorre, Helene Meisler, Doug Kass and other writers each trading day.